References
- World Health Organization. Global tuberculosis report. World Health Organization. Geneva, Switzerland; 2012
- Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res 2013;3:1–2
- Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008;322:1392–5
- Lenaerts J, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005;49:2294–301
- Palmer D, Thompson AM, Sutherland HS, et al. Synthesis and structure−activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J Med Chem 2010;53:282–94
- Thompson M, Blaser A, Anderson RF, et al. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3] oxazine (PA-824). J Med Chem 2009;52:637–45
- Thompson M, Sutherland HS, Palmer BD, et al. Synthesis and structure–activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J Med Chem 2011;54:6563–85
- Kmentova I, Sutherland HS Palmer BD, et al. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3] oxazine (PA-824). J Med Chem 2010;53:8421–39
- Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110:5959–67
- Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37:4130–46
- Castilho MS, Postigo MP, de Paula CB, et al. Two- and three-dimensional quantitative structure–activity relationships for a series of purine nucleoside phosphorylase inhibitors. Bioorg Med Chem 2006;14:516–27
- Cramer III RD, Bunce JD, Patterson DE, et al. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct-Act Relation 1988;7:18–25
- Wold S, Ruhe A, Wold H, et al. The collinearity problem in linear regression. the partial least squares (PLS) approach to generalized inverses. SIAM J Sci Stat Comput 1984;5:735–43
- Roy PP, Roy K. On some aspects of variable selection for partial least squares regression models. Quant Struct-Act Relation 2008;27:302–13
- Verma RP, Hansch C. An approach toward the problem of outliers in QSAR. Bioorg Med Chem 2005;13:4597–21
- Ghasemi B, tavakoli H. Improvement of the prediction power of the CoMFA and CoMSIA models on histamine H3 antagonists by different variable selection methods. Sci Pharm 2012;80:547–66
- Lei J, Du S, Li H, et al. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors. J Comput Aided Mol Des 2008;22:711–25
- Murugesan V, Prabhakar YS, Katti SB. CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents. J Mol Graphics Modell 2009;27:735–43
- Golbraikh A. Tropsha. Beware of q2! J Mol Graph Model 2002;20:269–76
- Roy K, Roy PP. On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008;27:302–13
- Roy K, Roy PP. On two novel parameters for validation of predictive QSAR models. Molecules 2009;14:1660–701
- Roy K, Roy PP. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques. Eur J Med Chem 2009;44:2913–22